Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment
نویسندگان
چکیده
منابع مشابه
Cellular immunity in breast cancer patients completing taxane treatment.
PURPOSE A field study of postchemotherapy immune functioning relative to the use of taxanes is reported. Immune responses in breast cancer patients were analyzed as a function of whether patients received taxane as part of their adjuvant chemotherapy. EXPERIMENTAL DESIGN Immune levels of 227 stage II/III breast cancer patients were measured immediately after surgery prior to chemotherapy and ...
متن کاملPrevalence of Fatty Liver in Breast Cancer Patients Undergoing Treatment
Background and purpose: Fatty liver is one of the most common liver diseases. Some treatments used in breast cancer may be associated with development of fatty liver. The present study aimed at investigating the prevalence of fatty liver in breast cancer patients. Materials and methods: In this cross-sectional study, 117 patients with breast cancer attending Ramsar Imam Sajjad Hospital in 2017...
متن کاملPredictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer.
PURPOSES/OBJECTIVES To identify the predictors of fatigue 30 days after completing adjuvant chemotherapy for breast cancer and whether differences are observed between a behavioral sleep intervention and a healthy-eating attention control group in predicting fatigue. DESIGN Descriptive, exploratory, secondary analysis of a randomized clinical trial. SETTING Outpatient oncology patients in a...
متن کاملTaxane resistance in breast cancer
Despite recent progress in the treatment of breast cancer, disease recurrence remains a major issue to curative therapy. One of the major clinical issues is the development of drug resistance. Taxane resistance is a big challenge because taxanes, either alone or in combination, is the first-line regimens for treating breast cancer. A hierarchy of resistant mechanisms are responsible for taxane ...
متن کاملGemcitabine-taxane experience in the treatment of metastatic breast cancer.
Management of metastatic breast cancer (MBC) is difficult and overall response rates (ORR) resulting from anthracycline and taxane-based regimens remain modest. The antimetabolite drug gemcitabine has been shown to have high activity when used as first-line treatment of MBC, particularly when incorporated into combined therapy regimens. Gemcitabine-containing regimens have also been used succes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2004
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-1016-03